Autolus Therapeutics plc Autolus Therapeutics plc

Autolus Therapeutics plc

AUTL

Rank in Stocks #14726
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily... Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
Share Price
$1.09
Last synced: 2026-11-17
Market Cap
$290.16M
Change (1 day)
-4.39%
Change (1 year)
-11.38%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
EPS for Autolus Therapeutics plc (AUTL)
EPS as of September 2026 TTM: $-0.97
According to Autolus Therapeutics plc's latest financial reports, its current EPS (TTM) is $-0.97. At the end of 2025 the company had an EPS of $-1.08, a decrease compared to its 2024 EPS of $-0.87.
EPS history for Autolus Therapeutics plc from 2015 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-0.97 -10.19%
2025 $-1.08 24.14%
2024 $-0.87 -27.50%
2023 $-1.20 -23.57%
2022 $-1.57 -20.30%
2021 $-1.97 -28.62%
2020 $-2.76 -4.17%
2019 $-2.88 190.91%
2018 $-0.99 -30.77%
2017 $-1.43 57.14%
2016 $-0.91 67.90%
2015 $-0.54 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$-0.89 -8.25%
US
$15.66 -1,714.43%
US
$-7.07 628.87%
US
$-5.29 445.36%
AU
$12.73 -1,412.60%
BE

Questions about Autolus Therapeutics plc's earnings per share (EPS)

What is Autolus Therapeutics plc's earnings per share (EPS)?

Autolus Therapeutics plc's earnings per share (EPS) over the last twelve months is $-0.97, as of Sep 2026.

What was Autolus Therapeutics plc's earnings per share (EPS) in 2025?

In 2025, Autolus Therapeutics plc's earnings per share (EPS) was $-1.08, compared with $-0.87 in 2024.

How has Autolus Therapeutics plc's earnings per share (EPS) changed since 2020?

From 2020 to 2025, Autolus Therapeutics plc's earnings per share (EPS) was highest in 2024 ($-0.87) and lowest in 2020 ($-2.76).

How does Autolus Therapeutics plc's earnings per share (EPS) compare with similar companies?

Autolus Therapeutics plc's earnings per share (EPS) ($-0.97) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.